# The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

> **NCT06388720** · PHASE2 · RECRUITING · sponsor: **National Cancer Center, Korea** · enrollment: 82 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Mitomycin-C
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT06388720
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-19
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388720, "The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06388720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*